Breast cancer: A comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites

Castagnetta, L.; D’Agostino, Catherine; Casto, M. Lo; Traina, Adele; Leake, R E

doi:10.1038/bjc.1981.252

Cited by 11 publications

(7 citation statements)

References 17 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Further study revealed that "unusual" estrogen metabolites (more polar derivatives as opposed to classical estrogens) represent the majority of urinary estrogens in breast cancer patients. 2 Subsequently, we showed that unusual metabolites are excreted in markedly greater amounts in endometrial cancer patients whose tumors are estrogen receptor (ER)-negative. 3 Using an original intact cell analysis, 4 we investigated sex steroid metabolism in a panel of human cancer cell lines, either hormone responsive or unresponsive, originating from human breast, endometrium, and prostate.…”

Section: Introductionsupporting

confidence: 93%

“…In 1977, we first noted that breast cancer patients have urinary levels of estrogens significantly higher than those found in healthy postmenopausal women 1. Further study revealed that “unusual” estrogen metabolites (more polar derivatives as opposed to classical estrogens) represent the majority of urinary estrogens in breast cancer patients 2. Subsequently, we showed that unusual metabolites are excreted in markedly greater amounts in endometrial cancer patients whose tumors are estrogen receptor (ER)‐negative 3.…”

Section: Introductionmentioning

confidence: 90%

See 1 more Smart Citation

Sex Steroids, Carcinogenesis, and Cancer Progression

Castagnetta

Granata²,

Cocciadiferro³

et al. 2004

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

ABSTRACT:The relationship between sex steroids and cancer has been studied for more than a century. Using an original intact cell analysis, we investigated sex steroid metabolism in a panel of human cancer cell lines, either hormone responsive or unresponsive, originating from human breast, endometrium, and prostate. We found that highly divergent patterns of steroid metabolism exist and that the catalytic preference (predominantly reductive or oxidative) is strictly associated with the steroid receptor status of cells. We explored intratissue concentrations and profiles of estrogens in a set of human breast tumors as compared to normal mammary tissues, also in relation to their estrogen receptor status. In particular, we showed that, with hydroxyestrogens representing the majority of all tissue estrogens, concentrations of individual metabolites, as well as their ratios, significantly differ when comparing normal tissue with cancer tissues or when they are related to the overall survival of cancer patients.

show abstract

Section: Introductionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 90%

Sex Steroids, Carcinogenesis, and Cancer Progression

Castagnetta

Granata²,

Cocciadiferro³

et al. 2004

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…Early studies from our own group have revealed that metabolic profiles of urinary estrogens may be useful to better categorize breast cancer patients in relation to their estrogen-sensitive status, response to hormone treatment, and overall prognosis (20). In this respect, metabolic profiles of estrogens in urine samples appear to be comparable to those obtained by measurement of intratissue amounts of estrogens.…”

Section: Introductionmentioning

confidence: 86%

A Traditional Mediterranean Diet Decreases Endogenous Estrogens in Healthy Postmenopausal Women

Carruba¹,

Granata²,

Pala³

et al. 2006

Nutrition and Cancer

View full text Add to dashboard Cite

Breast cancer incidence and mortality rates are markedly lower in the south than in the north of Europe. This has been ascribed to differences in lifestyle and, notably, dietary habits across European countries. However, little information exists on the influence of different dietary regimens on estrogens and, hence, on breast cancer risk. Here we report results of our MeDiet Project, a randomized, dietary intervention study aimed to assess the effect of a Mediterranean diet on the profiles of endogenous estrogens in healthy postmenopausal women. Out of the 230 women who initially volunteered to participate in the study, 115 were found to be eligible and were enrolled. Women were then randomly assigned into an intervention (n = 58) and a control (n = 57) group. Women in the intervention group adhered to a traditional, restricted Mediterranean diet for 6 mo, whereas women in the control group continued to follow their regular diet. Women in the intervention group changed their dietary regimen substantially, and this eventually led to a shift from a prevalent intake of animal fat and proteins to a prevalent intake of vegetable fat and proteins. Regarding urinary estrogens, no significant difference was observed between the intervention and control groups at baseline. After 6 mo, however, control women did not show any major change but women in the intervention group exhibited a significant decrease (over 40%) of total estrogen levels (P < 0.02). The largest part of this modification was based on a marked decrease of specific estrogen metabolites, including hydroxy- and keto-derivatives of estradiol or estrone. To our knowledge, this is the first report to show that a traditional Mediterranean diet significantly reduces endogenous estrogen. This may eventually lead to identify selected dietary components that more effectively decrease estrogens levels and, hence, provide a basis to develop dietary preventive measures for breast cancer.

show abstract

“…Early studies of our own group have suggested that urinary profiles of estrogens may be used to better categorize breast cancer patients in relation to their prognosis and response to treatment [Castagnetta et al, 1981]. In this respect, metabolic profiles of estrogens in urine appear to be comparable to those obtained by measurement of their intratissue concentrations, and can be potentially used as an indirect indication of endogenous estrogens.…”

Section: Circulating Steroidsmentioning

confidence: 97%

Estrogen and prostate cancer: An eclipsed truth in an androgen‐dominated scenario

Carruba¹

2007

J of Cellular Biochemistry

134

138

View full text Add to dashboard Cite

Prostate cancer is the commonest non-skin cancer in men. Incidence and mortality rates of this tumor vary strikingly throughout the world. Although several factors have been implicated to explain this remarkable variation, lifestyle and dietary factors may play a dominant role, with sex hormones behaving as intermediaries between exogenous factors and molecular targets in development and progression of prostate cancer. Human prostate cancer is generally considered a paradigm of androgen-dependent tumor; however, estrogen role in both normal and malignant prostate appears to be equally important. The association between plasma androgens and prostate cancer remains contradictory and mostly not compatible with the androgen hypothesis. Similar evidence apply to estrogens, although the ratio of androgen to estrogen in plasma declines with age. Apart from methodological problems, a major issue is to what extent circulating hormones can be considered representative of their intraprostatic levels. Both nontumoral and malignant human prostate tissues and cells are endowed with key enzymes of steroid metabolism, including 17betahydroxysteroid dehydrogenase (17betaHSD), 5beta-reductase, 3alpha/3betaHSD, and aromatase. A divergent expression and/or activity of these enzymes may eventually lead to a differential prostate accumulation of steroid derivatives having distinct biological activities, as it occurs for hydroxylated estrogens in the human breast. Locally produced or metabolically transformed estrogens may differently affect proliferative activity of prostate cancer cells. Aberrant aromatase expression and activity has been reported in prostate tumor tissues and cells, implying that androgen aromatization to estrogens may play a role in prostate carcinogenesis or tumor progression. Interestingly, many genes encoding for steroid enzymes are polymorphic, although only a few studies have supported their relation with risk of prostate cancer. In animal model systems estrogens, combined with androgens, appear to be required for the malignant transformation of prostate epithelial cells. Although the mechanisms underlying the hormonal induction of prostate cancer in experimental animals remain uncertain, there is however evidence to support the assumption that long term administration of androgens and estrogens results in an estrogenic milieu in rat prostates and in the ensuing development of dysplasia and cancer. Both androgen and estrogen have been reported to stimulate proliferation of cultured prostate cancer cells, primarily through receptor-mediated effects. As for estrogens, the two major receptor types, ERalpha and ERbeta, are expressed in both normal and diseased human prostate, though with a different cellular localization. Since these two receptors are different in terms of ligand binding, heterodimerization, transactivation, and estrogen response element activity, it is likely that an imbalance of their expression may be critical to determine the ultimate estrogen effects on prostate cancer cells. In prostate canc...

show abstract

Breast cancer: A comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites

Cited by 11 publications

References 17 publications

Sex Steroids, Carcinogenesis, and Cancer Progression

Sex Steroids, Carcinogenesis, and Cancer Progression

A Traditional Mediterranean Diet Decreases Endogenous Estrogens in Healthy Postmenopausal Women

Estrogen and prostate cancer: An eclipsed truth in an androgen‐dominated scenario

Contact Info

Product

Resources

About